Advanced

Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.

Asciutto, Giuseppe LU ; Edsfeldt, Andreas LU ; Dias, Nuno LU ; Nilsson, Jan LU ; Prehn, Cornelia ; Adamski, Jerzy and Goncalves, Isabel LU (2013) In Cardiovascular Pathology 22(6). p.438-443
Abstract
OBJECTIVES: To determine whether a long-term treatment with beta-blockers influences the inflammatory activity in carotid artery disease by reducing the carotid plaque levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), its enzymatic products lysophosphatidylcholine (lysoPCs), and of soluble urokinase plasminogen activator receptor (suPAR). MATERIALS AND METHODS: One hundred and thirty-four patients with significant symptomatic or asymptomatic carotid stenosis undergoing surgery were prospectively included and divided into two groups (Group A or B) based on the absence or presence of an on-going long-term oral treatment with beta-blockers. The harvested carotid plaques were analyzed for the levels of lysoPCs using mass... (More)
OBJECTIVES: To determine whether a long-term treatment with beta-blockers influences the inflammatory activity in carotid artery disease by reducing the carotid plaque levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), its enzymatic products lysophosphatidylcholine (lysoPCs), and of soluble urokinase plasminogen activator receptor (suPAR). MATERIALS AND METHODS: One hundred and thirty-four patients with significant symptomatic or asymptomatic carotid stenosis undergoing surgery were prospectively included and divided into two groups (Group A or B) based on the absence or presence of an on-going long-term oral treatment with beta-blockers. The harvested carotid plaques were analyzed for the levels of lysoPCs using mass spectrometry and Lp-PLA2 and suPAR by Enzyme-linked immunosorbent assay (ELISA). RESULTS: Plaques of patients on long-term treatment with beta-blockers revealed lower levels of Lp-PLA2 (Group A 0.752±0.393 ug/g vs. Group B 0.644±0.445 ug/g, P=.049) as well as suPAR (Group A 0.044±0.024 μg/g vs. Group B 0.036±0.025 μg/g, P=.028). Levels of Lp-PLA2 and suPAR were positively correlated (r=.637, P<.0001). Lp-PLA2 and suPAR levels were also correlated (P<.0001) with the three lysoPC species tested (lysoPC 16:0, lysoPC 18:0. lysoPC 18:1). All the above-mentioned findings were confirmed after correction for age, gender, hypertension, coronary artery disease, and statin usage. CONCLUSIONS: The reduced levels of Lp-PLA2 and suPAR in human carotid plaques of subjects on long-term treatment with beta-blockers suggest their possible protective role in plaque inflammation. Our findings support an even more selective Lp-PLA2 and suPAR inhibition as a possible strategy for the prevention of cardiovascular disease. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cardiovascular Pathology
volume
22
issue
6
pages
438 - 443
publisher
Elsevier
external identifiers
  • wos:000327153100004
  • pmid:23747086
  • scopus:84893660845
ISSN
1879-1336
DOI
10.1016/j.carpath.2013.04.005
language
English
LU publication?
yes
id
542b62e8-b36d-452b-8299-828626691b89 (old id 3913610)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23747086?dopt=Abstract
date added to LUP
2016-04-01 11:06:02
date last changed
2020-05-13 01:46:26
@article{542b62e8-b36d-452b-8299-828626691b89,
  abstract     = {OBJECTIVES: To determine whether a long-term treatment with beta-blockers influences the inflammatory activity in carotid artery disease by reducing the carotid plaque levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), its enzymatic products lysophosphatidylcholine (lysoPCs), and of soluble urokinase plasminogen activator receptor (suPAR). MATERIALS AND METHODS: One hundred and thirty-four patients with significant symptomatic or asymptomatic carotid stenosis undergoing surgery were prospectively included and divided into two groups (Group A or B) based on the absence or presence of an on-going long-term oral treatment with beta-blockers. The harvested carotid plaques were analyzed for the levels of lysoPCs using mass spectrometry and Lp-PLA2 and suPAR by Enzyme-linked immunosorbent assay (ELISA). RESULTS: Plaques of patients on long-term treatment with beta-blockers revealed lower levels of Lp-PLA2 (Group A 0.752±0.393 ug/g vs. Group B 0.644±0.445 ug/g, P=.049) as well as suPAR (Group A 0.044±0.024 μg/g vs. Group B 0.036±0.025 μg/g, P=.028). Levels of Lp-PLA2 and suPAR were positively correlated (r=.637, P&lt;.0001). Lp-PLA2 and suPAR levels were also correlated (P&lt;.0001) with the three lysoPC species tested (lysoPC 16:0, lysoPC 18:0. lysoPC 18:1). All the above-mentioned findings were confirmed after correction for age, gender, hypertension, coronary artery disease, and statin usage. CONCLUSIONS: The reduced levels of Lp-PLA2 and suPAR in human carotid plaques of subjects on long-term treatment with beta-blockers suggest their possible protective role in plaque inflammation. Our findings support an even more selective Lp-PLA2 and suPAR inhibition as a possible strategy for the prevention of cardiovascular disease.},
  author       = {Asciutto, Giuseppe and Edsfeldt, Andreas and Dias, Nuno and Nilsson, Jan and Prehn, Cornelia and Adamski, Jerzy and Goncalves, Isabel},
  issn         = {1879-1336},
  language     = {eng},
  number       = {6},
  pages        = {438--443},
  publisher    = {Elsevier},
  series       = {Cardiovascular Pathology},
  title        = {Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.},
  url          = {https://lup.lub.lu.se/search/ws/files/2379401/4144980.pdf},
  doi          = {10.1016/j.carpath.2013.04.005},
  volume       = {22},
  year         = {2013},
}